Navigation Links
Stem-cell therapy may provide new approach to fight infection
Date:7/1/2010

maging effects of inflammation were reduced while the ability to clear the infection was increased.

"Our results suggest that mesenchymal stem cells may provide a promising new approach for treating organ damage caused by severe infection and we are looking to test this in patients in the near future," said Dr. Stewart.

"Sepsis is a life-threatening medical condition caused by the body's response to infection," said Dr. Slutsky. "About a quarter of patients with severe sepsis die, and there are very few specific therapies for this devastating condition. That's why this study is potentially important."

"To achieve approximately 70 per cent reduction in mortality is pretty remarkable, even in a mouse model," said Dr. Liles. "By using a cell therapy, we can target multiple pathways that feed into this complex physiology rather than just one single pathway or factor."

Sepsis is the second leading cause of mortality in Canadian and U.S. intensive care units, resulting in more than 200,000 deaths each year and more than $16 billion in health care costs.


'/>"/>

Contact: Jennifer Paterson
jpaterson@ohri.ca
613-798-5555 x73325
Ottawa Hospital Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
2. Stem-cell disruption induces skull deformity, UR study shows
3. Chemists influence stem-cell development with geometry
4. UCR scientists identify stem-cell genes that help form plant organs
5. Scripps research scientists identify compounds for stem-cell production from adult cells
6. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
7. Reprogramming the debate: stem-cell finding alters ethical controversy
8. Gene therapy a step closer to mass production
9. UF oncologists fight leukemia with two-pronged therapy, clinical trials planned
10. McGill team discovers a piece of the puzzle for individualized cancer therapy via gene silencing
11. Making personalized lung cancer therapy a reality in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... ending its promotional pricing and making the Wocket generally available ... Savin , Head of Marketing said, "We,ve extended the opportunity ... end of May. To get your wocket at this special ... the store on June 1, you,ll receive a unique code ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... will join researchers from around the world to celebrate ... treaty designed to reduce the hole in Earth,s protective ... the meeting from Sept. 23-26 in Athens, Greece. NASA ... the recovery of the ozone layer. "The Montreal ...
... (UWM) are working with local company PhysioGenix to investigate ... researching diseases like depression, anxiety, schizophrenia and ADHD. ... by researchers at the Medical College of Wisconsin (MCW) ... diseases. Called consomic rats, they were produced by replacing ...
... Fred Dryer has a lofty goal: end the nation,s ... potentially major benefits for energy security and the environment ... knowledge of jet fuels while developing practical, innovative energy ... sources feasible, they need to be compatible with petroleum ...
Cached Biology News:NASA keeps eye on ozone layer amid Montreal Protocol's success 2NASA keeps eye on ozone layer amid Montreal Protocol's success 3A new kind of rat model 2Green skies: Engineer's work may reduce jet travel's role in global warming 2Green skies: Engineer's work may reduce jet travel's role in global warming 3Green skies: Engineer's work may reduce jet travel's role in global warming 4
(Date:6/2/2015)... TORONTO , June 2, 2015 /PRNewswire/ - Aptose ... clinical-stage company developing new therapeutics that target the underlying ... and Drug Administration (FDA) has granted the company orphan ... myeloid leukemia (AML). APTO-253, a first-in-class inducer of the ... a Phase Ib clinical trial in patients with AML, ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... of the "Bioburden Testing Market by Product , ... report to their offering. The bioburden ... 2019 from $354.4 Million in 2014, growing at a ... the basis of products, the microbial limit testing market ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ) has announced the addition ... Strategy and Forecasts - 2015 to 2019" report ... Market Size, Strategy and Forecasts - 2015 to 2019" ... of pages of information including a complete list of ... help understand test pricing in detail. See ...
(Date:6/2/2015)... Meet ARGUS, The World,s First ... Read People. Analyze emotions and predict actions. Explore a ... very first Responsive-RPG: "The Eye: Genesis".      ... , , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 ... inner feelings - and those of others. Being able ...
Breaking Biology Technology:Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Bioburden Testing Market 2015 - Global Forecasts to 2019 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3
... ThirdBiotech,( http://www.thirdbiotech.com ), a biotechnology networking ... in Arizona. (Logo: http://www.newscom.com/cgi-bin/prnh/20070911/LATU119LOGO ) ... the group to foster,networking and collaboration for ... the state. "It,s important we start finding ...
... 11 Dynatronics,Corporation (Nasdaq: DYNT ) will ... ended June 30, 2007 during the morning of ... conference call for investors later that,day at 1:00 ... quarter and fiscal year.,Those interested in participating should ...
... DALLAS, Sept. 11 ACCESS PHARMACEUTICALS, INC.,(OTC ... business columnist,Gene Marcial of BusinessWeek, highlighted Access ... 17, 2007. The article is also available,on ... Street, column. The article focused upon ...
Cached Biology Technology:Access Highlighted in Recent BusinessWeek Article 2
... siSolutions siRNA Custom Synthesis Service ... duplex RNA to knockdown any ... (19 RNA base pairs with ... 27-mers, or other lengths of ...
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
...
Biology Products: